<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="studies that probably protect human subjects from viruses and ameliorate" exact="vascular" post="dysfunction caused by metabolic disorders, especially lifestyle-related diseases. In"/>
 <result pre="other biological activities. Monostroma nitidum rhamnan sulfate antithrombotic effect antivirus" exact="vascular" post="endothelium dysfunction 1. Introduction Seaweeds have traditionally been consumed"/>
 <result pre="Bay in Mie Prefecture, accounting for about 70% of the" exact="total" post="production in Japan. M. nitidum is a health-promoting food"/>
 <result pre="an inhibitor of DNA synthesis used as a medication for" exact="herpes" post="simplex virus type 1 and type 2, which cause"/>
 <result pre="DNA synthesis used as a medication for herpes simplex virus" exact="type 1" post="and type 2, which cause strong inflammatory responses in"/>
 <result pre="as a medication for herpes simplex virus type 1 and" exact="type 2," post="which cause strong inflammatory responses in the skin, mouth,"/>
 <result pre="viruses, they are more likely to induce mutations in the" exact="viral" post="DNA or RNA. To overcome this problem, researchers sought"/>
 <result pre="of RS revealed that RS showed suppressing effects on human" exact="immunodeficiency" post="virus (HIV), human cytomegalovirus (HCMV), and herpes simplex virus"/>
 <result pre="effects on human immunodeficiency virus (HIV), human cytomegalovirus (HCMV), and" exact="herpes" post="simplex virus types 1 and 2 (HSV-I and -II)"/>
 <result pre="immunodeficiency virus (HIV), human cytomegalovirus (HCMV), and herpes simplex virus" exact="types 1 and 2" post="(HSV-I and -II) [6,9,10]. Recently, Terasawa et al. showed"/>
 <result pre="RS has an antiviral effect on enveloped viruses, such as" exact="measles" post="virus, mump virus, influenza A virus, and human corona"/>
 <result pre="rate, and RS directly binds to viruses and thereby prevents" exact="viral" post="absorption to tissue cells [12], suggesting that it can"/>
 <result pre="oral administration of RS in influenza A virusâ€&quot;infected mice suppressed" exact="viral" post="proliferation and weight loss and stimulated neutralizing antibody production"/>
 <result pre="influenza virus hemagglutinin (HA), which is a glycoprotein on the" exact="viral" post="envelope and important for host cell binding. Both antiviral"/>
 <result pre="stimulating activities of RS may contribute to the suppression of" exact="viral" post="proliferation in vivo [13]. 3.2. Anti-Obesity and Anti-Hypercholesterolemic Effects"/>
 <result pre="contains large amounts of dietary fibers and is reported to" exact="lower" post="serum cholesterol levels and neutral fats through carrageenan [27]."/>
 <result pre="the extracted RS, a soluble fiber, is effective for treating" exact="obesity" post="and obesity-related diseases, including hepatic steatosis, diabetes, and hyperlipidemia,"/>
 <result pre="fiber, is effective for treating obesity and obesity-related diseases, including" exact="hepatic steatosis," post="diabetes, and hyperlipidemia, the zebrafish was used to assess"/>
 <result pre="has anti-obesity effects. We conducted a clinical trial on 16" exact="adult" post="males with high cholesterol levels [24]. Their serum cholesterol"/>
 <result pre="LDL/HDL cholesterol ratio low and prevents lifestyle-related diseases such as" exact="obesity" post="and hyperlipidemia. 3.3. Anti-Glycemia Effect of RS Kamimura et"/>
 <result pre="that the M. nitidum powder and RS are useful for" exact="diabetes mellitus." post="In general, dietary fiber has the effect of suppressing"/>
 <result pre="Antithrombotic Effects of RS Risk factors for the development of" exact="thrombosis" post="include aging, various environmental factors, clinical conditions, and stress."/>
 <result pre="thrombosis include aging, various environmental factors, clinical conditions, and stress." exact="Thrombosis" post="is a clinical condition that occurs when a pathological"/>
 <result pre="occurs when a pathological thrombus develops in the blood vessel." exact="Platelet" post="aggregation, blood clotting, and vascular endothelial inflammation are alleged"/>
 <result pre="develops in the blood vessel. Platelet aggregation, blood clotting, and" exact="vascular" post="endothelial inflammation are alleged to be three major factors"/>
 <result pre="be three major factors closely related to thrombus formation in" exact="blood vessels" post="(Virchowâ€™s triad for thrombosis) (Figure 4) [30,31]. Rudolf K."/>
 <result pre="and fibrinolysis factors; and (3) vessel wall, such as abnormal" exact="vascular" post="endothelial inflammation. Even today, these three factors are important"/>
 <result pre="developing medicines to treat and prevent thrombotic disorders [32,33]. 3.4.1." exact="Blood" post="Coagulation and Platelet Aggregation under Vascular Endothelial Cell Inflammation"/>
 <result pre="treat and prevent thrombotic disorders [32,33]. 3.4.1. Blood Coagulation and" exact="Platelet" post="Aggregation under Vascular Endothelial Cell Inflammation It has been"/>
 <result pre="thrombotic disorders [32,33]. 3.4.1. Blood Coagulation and Platelet Aggregation under" exact="Vascular" post="Endothelial Cell Inflammation It has been recognized that the"/>
 <result pre="factors contributing to the formation of pathological thrombi in the" exact="blood vessels" post="are pathological changes, such as inflammation of the vascular"/>
 <result pre="blood vessels are pathological changes, such as inflammation of the" exact="vascular" post="endothelium [34,35]. Factors such as aging, obesity, hypertension, diabetes,"/>
 <result pre="obesity, hypertension, diabetes, various types of stress, and smoking induce" exact="chronic" post="damage to the endothelium. In general, normal vascular endothelial"/>
 <result pre="smoking induce chronic damage to the endothelium. In general, normal" exact="vascular" post="endothelial cells express various molecules that inhibit thrombus formation."/>
 <result pre="platelet aggregation; plasminogen activator inhibitor-1 (PAI-1), which attenuates fibrinolysis; and" exact="tumor" post="necrosis factor-Î± (TNF-Î±), which induces an inflammatory response (Table"/>
 <result pre="molecules, adhesion of leukocytes to the endothelium, and proliferation of" exact="vascular" post="muscle cells. These changes lead to the development and"/>
 <result pre="adhesion of leukocytes to the endothelium, and proliferation of vascular" exact="muscle" post="cells. These changes lead to the development and progression"/>
 <result pre="lead to the development and progression of arteriosclerosis, unstable or" exact="ruptured" post="plaques, the generation of a thrombin-induced coagulation thrombus, and"/>
 <result pre="a thrombin-induced coagulation thrombus, and ultimately to various types of" exact="thrombosis" post="(Figure 5). Endothelial injury induced by various factors promotes"/>
 <result pre="and increased inflammatory response, giving rise to arteriosclerosis, unstable or" exact="ruptured" post="plaques, the generation of a thrombin-induced coagulation thrombus, and"/>
 <result pre="thrombin-induced coagulation thrombus, and ultimately various types of thrombosis. In" exact="infectious diseases," post="various types of pathogen-derived molecules (pathogen-associated molecular patterns: PAMPs"/>
 <result pre="innate immune system [37,38]. For example, bacterial-membrane-derived lipopolysaccharides (LPS) cause" exact="acute" post="damage to endothelial cells and body tissue cells [39]."/>
 <result pre="in the capillary of various organs and the induction of" exact="disseminated intravascular coagulation" post="(DIC) [41], which may result in multiple-organ failure (MOF)"/>
 <result pre="result in multiple-organ failure (MOF) [42] or severe bleeding. Moreover," exact="hemolytic uremic syndrome" post="(HUS) caused by Escherichia coli O-157 infection [43], sinusoidal"/>
 <result pre="multiple-organ failure (MOF) [42] or severe bleeding. Moreover, hemolytic uremic" exact="syndrome" post="(HUS) caused by Escherichia coli O-157 infection [43], sinusoidal"/>
 <result pre="Moreover, hemolytic uremic syndrome (HUS) caused by Escherichia coli O-157" exact="infection" post="[43], sinusoidal obstructive syndrome (SOS)/veno-occlusive disease (VOD) [44,45], and"/>
 <result pre="(HUS) caused by Escherichia coli O-157 infection [43], sinusoidal obstructive" exact="syndrome" post="(SOS)/veno-occlusive disease (VOD) [44,45], and transplantation-associated thrombotic microangiopathy (TA-TMA)"/>
 <result pre="by Escherichia coli O-157 infection [43], sinusoidal obstructive syndrome (SOS)/veno-occlusive" exact="disease" post="(VOD) [44,45], and transplantation-associated thrombotic microangiopathy (TA-TMA) [46] are"/>
 <result pre="quite important to prevent the inflammation of the endothelium. 3.4.2." exact="Platelet" post="Aggregation Inhibitory Effect of RS Formation of thrombi due"/>
 <result pre="due to enhanced platelet aggregation is known to cause artery" exact="thrombosis" post="[47,48]. To identify the effects that RS has on"/>
 <result pre="be useful as a food for preventing arterial thrombosis. 3.4.3." exact="Blood" post="Coagulation Inhibitory Effect of RS The formation of a"/>
 <result pre="thrombus due to activation of the blood coagulation system in" exact="blood vessels" post="is thought to cause mainly venous thrombosis. To examine"/>
 <result pre="(PT), which measures extrinsic coagulation ability, and on the activated" exact="partial" post="thromboplastin time (APTT), which measures intrinsic coagulation ability. Heparin"/>
 <result pre="preventing the development of venous thrombosis. 3.4.4. Inhibition Mechanism of" exact="Blood" post="Coagulation by RS and Heparin The anticoagulant heparin exists"/>
 <result pre="effects on thrombin and factor Xa in the presence or" exact="absence of" post="purified AT were analyzed. As shown in Figure 8a,"/>
 <result pre="expression in the endothelial cells both in the presence and" exact="absence of" post="LPS (Figure 9d). Likewise, RS suppressed significantly the elevation"/>
 <result pre="RS was shown to strongly attenuate inflammatory injury in cultured" exact="vascular" post="endothelial cells. RS is suggested to be a novel"/>
 <result pre="suggested to be a novel anticoagulant and anti-inflammatory substance for" exact="vascular" post="endothelial cells. 4. Closing Remarks M. nitidum RS has"/>
 <result pre="a wide range of health-promotion effects in lifestyle-related disordersâ€&quot;it prevents" exact="obesity" post="and the elevation of LDL cholesterol and suppresses the"/>
 <result pre="glucose levels [24,25,26]. It was also shown to improve various" exact="vascular" post="dysfunctions caused by lifestyle-related diseases. In addition to the"/>
 <result pre="effects of lifestyle-related disorders, RS may be important in combating" exact="viral" post="epidemics. Figure 10 shows the possibility that oral ingestion"/>
 <result pre="10 shows the possibility that oral ingestion of RS prevents" exact="viral infection," post="thrombotic disease, hypercholesterolemia, hyperglycemia, and so on. RS is"/>
 <result pre="a major challenge. As is often said, â€œhumans age as" exact="blood vessels" post="ageâ€�; however, it is considered that RS is an"/>
 <result pre="extracted from Monostroma nitidum attenuates blood coagulation and inflammation of" exact="vascular" post="endothelial cellsJ. Nat. Med.20197361461910.1007/s11418-019-01289-530796650 15.LiuX.HaoJ.HeX.WangS.CaoS.QinL.MaoW.A rhamnan-type sulfated polysaccharide with"/>
 <result pre="Polym.20118539440010.1016/j.carbpol.2011.02.042 22.RopellatoJ.CarvalhoM.M.FerreiraL.G.NosedaM.D.ZuconelliC.R.GoncalvesA.G.DucattiD.R.KenskiJ.C.NasatoP.L.WinnischoferS.M.et al.Sulfated heterorhamnans from the green seaweed Gayralia oxysperma:" exact="Partial" post="depolymerization, chemical structure and antitumor activityCarbohydr. Polym.201511747648510.1016/j.carbpol.2014.09.08925498661 23.YamamotoY.OzonoM.OishiT.OshimaK.MitsuikiS.KakiharaH.MukaeK.Hyaluronidase-inhibitory activity"/>
 <result pre="hypercholesterolemiaJ. New Rem. Clin.20065517631770 25.ZangL.ShimadaY.TanakaT.NishimuraN.Rhamnan sulphate from Monostroma nitidum attenuates" exact="hepatic steatosis" post="by suppressing lipogenesis in a diet-induced obesity zebrafish modelJ."/>
 <result pre="nitidum attenuates hepatic steatosis by suppressing lipogenesis in a diet-induced" exact="obesity" post="zebrafish modelJ. Funct. Foods20151736437010.1016/j.jff.2015.05.041 26.KamimuraY.HashiguchiK.NagataY.SakaT.YoshidaM.MakinoY.AmanoH.Inhibitory effects of edible green"/>
 <result pre="gastric emptying, postprandial blood glucose and insulin in patients with" exact="type 2" post="diabetesAsia Pac. J. Clin. Nutr.20142321021824901089 30.KumarD.R.HanlinE.GlurichI.MazzaJ.J.YaleS.H.Virchowâ€™s contribution to the"/>
 <result pre="Pac. J. Clin. Nutr.20142321021824901089 30.KumarD.R.HanlinE.GlurichI.MazzaJ.J.YaleS.H.Virchowâ€™s contribution to the understanding of" exact="thrombosis" post="and cellular biologyClin. Med. Res.2010816817210.3121/cmr.2009.86620739582 31.BagotC.N.AryaR.Virchow and his triad:"/>
 <result pre="of thrombogenesis in atrial fibrillation: Virchowâ€™s triad revisitedLancet200937315516610.1016/S0140-6736(09)60040-419135613 33.HosseinzadeganH.TaftiD.K.Prediction of" exact="Thrombus" post="Growth: Effect of Stenosis and Reynolds NumberCardiovasc. Eng. Technol.2017816418110.1007/s13239-017-0304-328470538"/>
 <result pre="fibrillation: Virchowâ€™s triad revisitedLancet200937315516610.1016/S0140-6736(09)60040-419135613 33.HosseinzadeganH.TaftiD.K.Prediction of Thrombus Growth: Effect of" exact="Stenosis" post="and Reynolds NumberCardiovasc. Eng. Technol.2017816418110.1007/s13239-017-0304-328470538 34.BadimonL.VilahurG.Thrombosis formation on atherosclerotic"/>
 <result pre="Targets2015152910.2174/1871529X1566615010811082125567340 40.TomuraS.NakamuraY.DeguchiF.ChidaY.OhnoY.KodamaS.HayashiT.SuzukiK.MarumoF.Plasma von Willebrand factor and thrombomodulin as markers of" exact="vascular" post="disorders in patients undergoing regular hemodialysis therapyThromb. Res.19905841341910.1016/0049-3848(90)90212-U2162087 41.ItoT.PAMPs"/>
 <result pre="DICJ. Intensiv. Care201426710.1186/s40560-014-0065-0 42.YangR.ZouX.TenhunenJ.TonnessenT.I.HMGB1 and extracellular histones significantly contribute to" exact="systemic" post="inflammation and multiple organ failure in acute liver failureMediators"/>
 <result pre="significantly contribute to systemic inflammation and multiple organ failure in" exact="acute" post="liver failureMediators Inflamm.20172017592807810.1155/2017/592807828694564 43.KarpmanD.LoosS.TatiR.ArvidssonI.Haemolytic uraemic syndromeJ. Intern. Med.201728112314810.1111/joim.1254627723152 44.RichardsonP.G.GruppS.A.PagliucaA.KrishnanA.HoV.T.CorbaciogluS.Defibrotide"/>
 <result pre="Med.201728112314810.1111/joim.1254627723152 44.RichardsonP.G.GruppS.A.PagliucaA.KrishnanA.HoV.T.CorbaciogluS.Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction" exact="syndrome" post="with multiorgan failureIntern. J. Hematol. Oncol.20176759310.2217/ijh-2017-001530302228 45.VallaD.C.Cazals-HatemD.Sinusoidal obstruction syndromeClin."/>
 <result pre="and comparison between renal TA-TMA and intestinal TA-TMA: Autopsy studyBiol." exact="Blood" post="Marrow Transplant.20202617818810.1016/j.bbmt.2019.08.02531491486 47.VanhoutteP.M.ShimokawaH.TangE.H.FeletouM.Endothelial dysfunction and vascular diseaseActa Physiol. (Oxf.)200919619322210.1111/j.1748-1716.2009.01964.x19220204"/>
 <result pre="intestinal TA-TMA: Autopsy studyBiol. Blood Marrow Transplant.20202617818810.1016/j.bbmt.2019.08.02531491486 47.VanhoutteP.M.ShimokawaH.TangE.H.FeletouM.Endothelial dysfunction and" exact="vascular" post="diseaseActa Physiol. (Oxf.)200919619322210.1111/j.1748-1716.2009.01964.x19220204 48.SpragueA.H.KhalilR.A.Inflammatory cytokines in vascular dysfunction and"/>
 <result pre="47.VanhoutteP.M.ShimokawaH.TangE.H.FeletouM.Endothelial dysfunction and vascular diseaseActa Physiol. (Oxf.)200919619322210.1111/j.1748-1716.2009.01964.x19220204 48.SpragueA.H.KhalilR.A.Inflammatory cytokines in" exact="vascular" post="dysfunction and vascular diseaseBiochem. Pharmacol.20097853955210.1016/j.bcp.2009.04.02919413999 49.NaderH.B.ChavanteS.F.dos-SantosE.A.OliveiraF.W.de-PaivaJ.F.JerÃ´nimoS.M.B.MedeirosG.F.de-AbreuL.R.D.LeiteE.L.de-Sousa-FilhoJ.F.et al.Heparan sulfates and"/>
 <result pre="vascular diseaseActa Physiol. (Oxf.)200919619322210.1111/j.1748-1716.2009.01964.x19220204 48.SpragueA.H.KhalilR.A.Inflammatory cytokines in vascular dysfunction and" exact="vascular" post="diseaseBiochem. Pharmacol.20097853955210.1016/j.bcp.2009.04.02919413999 49.NaderH.B.ChavanteS.F.dos-SantosE.A.OliveiraF.W.de-PaivaJ.F.JerÃ´nimoS.M.B.MedeirosG.F.de-AbreuL.R.D.LeiteE.L.de-Sousa-FilhoJ.F.et al.Heparan sulfates and heparins: Similar compounds"/>
 <result pre="Med. Biol. Res.19993252953810.1590/S0100-879X199900050000510412563 50.MoyF.J.SeddonA.P.CampbellE.B.BohlenP.PowersR.1H, 15N, 13C and 13CO assignments and" exact="secondary" post="structure determination of basic fibroblast growth factor using 3D"/>
 <result pre="enhance the tumoricidal activity of antitumor monoclonal antibodies in murine" exact="tumor" post="modelsJ. Immunol.200417379780610.4049/jimmunol.173.2.79715240666 58.HaseK.KawanoK.NochiT.PontesG.S.FukudaS.EbisawaM.KadokuraK.TobeT.FujimuraY.KawanoS.et al.Uptake through glycoprotein 2 of FimH(+)"/>
 <result pre="Schematic diagram of the mechanism of thrombotic disorders caused by" exact="vascular" post="endothelial inflammation associated with lifestyle-related diseases and various clinical"/>
 <result pre="(â—�) and heparin (â—‹) on intrinsic coagulation measured by activated" exact="partial" post="thromboplastin time (APTT). The data are cited from [14]."/>
 <result pre="heparin on inhibition of blood coagulation in the presence or" exact="absence of" post="antithrombin (AT). (a) Effect of RS (2 Î¼g/mL) and"/>
 <result pre="on inhibition of thrombin (2.5 nM) in the presence or" exact="absence of" post="AT (5 nM). (b) Effect of RS (2 Î¼g/mL)"/>
 <result pre="inhibition of factor Xa (12.5 nM) in the presence or" exact="absence of" post="AT (25 nM). Significant difference in values between the"/>
 <result pre="trial [26] marinedrugs-18-00228-t002_Table 2Table 2 Antithrombotic factors expressed in normal" exact="vascular" post="endothelium and its functional mechanisms. Substance Function Antithrombotic Mechanism"/>
 <result pre="of coagulation initiation via inhibition of TF, FXa and FVIIa" exact="Protein" post="S Activator of APC and TFPI Enhancement of APC-mediated"/>
 <result pre="Activation of plasminogen to plasmin IL-4 Anti-inflammatory cytokine Inhibition of" exact="vascular" post="endothelial inflammation IL-10 Anti-inflammatory cytokine Inhibition of vascular endothelial"/>
 <result pre="Inhibition of vascular endothelial inflammation IL-10 Anti-inflammatory cytokine Inhibition of" exact="vascular" post="endothelial inflammation TM, thrombomodulin; APC, activated protein C; TAFI,"/>
 <result pre="IL-10, interleukin-10. marinedrugs-18-00228-t003_Table 3Table 3 Thrombogenetic factors expressed in injured" exact="vascular" post="endothelium and its functional mechanisms. Substance Function Thrombus Formation"/>
 <result pre="in injured vascular endothelium and its functional mechanisms. Substance Function" exact="Thrombus" post="Formation Mechanism TF Activator of blood coagulation Activation of"/>
 <result pre="PAI-1 Plasminogen activator inhibitor Inhibition of t-PA-mediated plasminogen activation TNF-Î±" exact="Inflammatory" post="cytokine Induction of inflammation, cell adhesion molecules, and apoptosis"/>
 <result pre="A2; PAF, platelet activating factor; PAI-1, plasminogen activator inhibitor-1; TNF-Î±," exact="tumor" post="necrosis factor-Î±; ET-1, endothelin-1; Mac-1, macrophage-1 antigen (integrin Î±MÎ²2);"/>
</results>
